β-arrestin-1 drives endothelin-1-mediated podocyte activation and sustains renal injury

Simona Buelli, Laura Rosanò, Elena Gagliardini, Daniela Corna, Lorena Longaretti, Anna Pezzotta, Luca Perico, Sara Conti, Paola Rizzo, Rubina Novelli, Marina Morigi, Carlamaria Zoja, Giuseppe Remuzzi, Anna Bagnato, Ariela Benigni

Research output: Contribution to journalArticlepeer-review

Abstract

Activation of endothelin-A receptor (ETAR) by endothelin-1 (ET-1) drives epithelial-to-mesenchymal transition in ovarian tumor cells through β-arrestin signaling. Here, we investigated whether this pathogenetic pathway could affect podocyte phenotype in proliferative glomerular disorders. In cultured mouse podocytes, ET-1 caused loss of the podocyte differentiation marker synaptopodin and acquisition of the mesenchymal marker α-smooth muscle actin. ET-1 promoted podocyte migration via ET AR activation and increased β-arrestin-1 expression. Activated ETAR recruited β-arrestin-1 to form a trimeric complex with Src leading to epithelial growth factor receptor (EGFR) transactivation and β-catenin phosphorylation, which promoted gene transcription of Snail. Increased Snail expression fostered ET-1-induced migration as confirmed by Snail knockdown experiments. Silencing of β-arrestin-1 prevented podocyte phenotypic changes and motility and inhibited ETAR-driven signaling. In vitro findings were confirmed in doxorubicin (Adriamycin)-induced nephropathy. Mice receiving Adriamycin developed renal injury with loss of podocytes and hyperplastic lesion formation; β-arrestin-1 expression increased in visceral podocytes and in podocytes entrapped in pseudo-crescents. Administration of the selective ETAR antagonist sitaxsentan prevented podocyte loss, formation of the hyperplastic lesions, and normalized expression of glomerular β-arrestin-1 and Snail. Increased β-arrestin-1 levels in podocytes retrieved from crescents of patients with proliferative glomerulopathies confirmed the translational relevance of these findings and suggest the therapeutic potential of ETAR antagonism for a group of diseases still needing a specific treatment.

Original languageEnglish
Pages (from-to)523-533
Number of pages11
JournalJournal of the American Society of Nephrology
Volume25
Issue number3
DOIs
Publication statusPublished - Mar 2014

ASJC Scopus subject areas

  • Nephrology

Fingerprint

Dive into the research topics of 'β-arrestin-1 drives endothelin-1-mediated podocyte activation and sustains renal injury'. Together they form a unique fingerprint.

Cite this